Tradestie Institutional Equity Comparison Engine
NIVF vs CDT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CDT Overall Edge
CDT Captures Institutional Edge (2โ0 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CDT Equity Inc. Common Stock (CDT) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, NIVF trades at N/M Forward P/E with -238.2% operating margin (-4.7% YoY revenue) versus CDT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NIVF sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
NIVF N/M vs CDT N/M Fwd P/E
Growth & Margin Winner
CDT
Op Margin -238.2% vs 0.0% ยท YoY -4.7% vs +0.0%
Momentum & Technical Winner
CDT
1Y -91.8% vs -86.8% ยท 52W Pos 0% vs 2%
Options & Structure Winner
Tie
BREAKDOWN (N/A IV) vs BREAKDOWN (N/A IV)
NIVF
NASDAQ
NewGenIvf Group Limited Class A ordinary shares
Services-Misc Health & Allied Services, Nec
$0.03
-23.14% 1D
Market Cap
$98,000
1M Return
-81.93%
1Y Return
-91.82%
Forward P/E
N/M
Unified AI Score
47.7 / 100
HOLD
Tech 43.0
Fund 49.0
Flow 50.0
Mom 60.0
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NIVF -91.82%
CDT -86.78%
Spread: +5.04 pp (CDT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NIVF TTM Op. Margin: -238.2%
CDT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NIVF vs CDT. Trailing 12-month operating profitability (NIVF -238.2% vs CDT 0.0%) and valuation multiples (NIVF N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NIVF | CDT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $98,000 | $507,528 | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -4.7% | +0.0% | Higher Growth | CDT |
| Operating Margin (TTM) Profitability | -238.2% | 0.0% | Higher Margin | CDT |
| Net Profit Margin Profitability | 24.2% | 0.0% | Higher Margin | NIVF |
| Return on Equity (ROE) Capital Efficiency | 5.5% | -69.7% | Higher ROE | NIVF |
| 52-Week Range Position Momentum | 0% ($0โ$3) | 2% ($0โ$11) | Stronger Trend | CDT |
| Beta / 30D Volatility Risk Regime | 0.05ฮฒ ยท 3040% Vol | -17.75ฮฒ ยท 10175% Vol | Lower Realized Risk | NIVF |
| Unified Institutional Score Composite Signal | 47.7 / 100 (HOLD) | 31.6 / 100 (SELL) | Higher Composite | NIVF |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NIVF vs CDT Buy Guide
NIVF
BREAKDOWN
19d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NIVF nor CDT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.